{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T02:17:19Z","timestamp":1790216239245,"version":"4.1.0"},"reference-count":44,"publisher":"American Society of Hematology","issue":"7","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2019,4,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Patients with chronic graft-versus-host disease (cGVHD) have a paucity of regulatory CD4 T cells (CD4Tregs) that mediate peripheral tolerance. In clinical trials, daily low-dose interleukin-2 (IL-2) has been administered safely for prolonged periods in patients with steroid-refractory cGVHD. Peripheral CD4Tregs expand dramatically in all patients during IL-2 therapy but clinical improvement was observed in \u223c50% of patients. Here, we examined the impact of low-dose IL-2 therapy on functional T-cell markers and the T-cell repertoire within CD4Tregs, conventional CD4 T cells (CD4Tcons), and CD8+ T cells. IL-2 had profound effects on CD4Tregs homeostasis in both response groups including selective expansion of the naive subset, improved thymic output, and increased expression of Ki67, FOXP3, and B-cell lymphoma 2 within CD4Tregs. Similar changes were not seen in CD4Tcons or CD8 T cells. Functionally, low-dose IL-2 enhanced, in vitro, CD4Treg-suppressive activity in both response groups, and all patient CD4Tcons were similarly suppressed by healthy donor CD4Tregs. High-throughput sequencing of the T-cell receptor \u03b2 (TCR\u03b2) locus demonstrated that low-dose IL-2 therapy increased TCR repertoire diversity and decreased evenness within CD4Tregs without affecting CD4Tcons or CD8 T cells. Using clone-tracking analysis, we observed rapid turnover of highly prevalent clones in CD4Tregs as well as the conversion of CD4Tcons to CD4Tregs. After 12 weeks of daily IL-2, clinical responders had a greater influx of novel clones within the CD4Treg compartment compared with nonresponders. Further studies to define the function and specificity of these novel CD4Treg clones may help establish the mechanisms whereby low-dose IL-2 therapy promotes immune tolerance.<\/jats:p>","DOI":"10.1182\/bloodadvances.2018027474","type":"journal-article","created":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T20:45:22Z","timestamp":1554151522000},"page":"984-994","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":29,"title":["Functional analysis of clinical response to low-dose IL-2 in patients with refractory chronic graft-versus-host disease"],"prefix":"10.1182","volume":"3","author":[{"given":"Jennifer S.","family":"Whangbo","sequence":"first","affiliation":[{"name":"Division of Hematology-Oncology, Boston Children\u2019s Hospital, Boston, MA;"},{"name":"Department of Pediatric Oncology and"},{"name":"Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston MA;"},{"name":"Harvard Medical School, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haesook T.","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Biostatistics & Computational Biology, Dana-Farber Cancer Institute, Boston, MA;"},{"name":"Harvard School of Public Health, Boston, MA; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Nikiforow","sequence":"additional","affiliation":[{"name":"Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston MA;"},{"name":"Harvard Medical School, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Koreth","sequence":"additional","affiliation":[{"name":"Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston MA;"},{"name":"Harvard Medical School, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana C.","family":"Alho","sequence":"additional","affiliation":[{"name":"Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston MA;"},{"name":"Harvard Medical School, Boston, MA;"},{"name":"Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bryn","family":"Falahee","sequence":"additional","affiliation":[{"name":"Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston MA;"},{"name":"Harvard Medical School, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soomin","family":"Kim","sequence":"additional","affiliation":[{"name":"Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston MA;"},{"name":"Harvard Medical School, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharine","family":"Dusenbury","sequence":"additional","affiliation":[{"name":"Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston MA;"},{"name":"Harvard Medical School, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie J.","family":"Fields","sequence":"additional","affiliation":[{"name":"Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston MA;"},{"name":"Harvard Medical School, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carol G.","family":"Reynolds","sequence":"additional","affiliation":[{"name":"Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston MA;"},{"name":"Harvard Medical School, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"III","given":"Edwin P.","family":"Alyea","sequence":"additional","affiliation":[{"name":"Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston MA;"},{"name":"Harvard Medical School, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Armand","sequence":"additional","affiliation":[{"name":"Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston MA;"},{"name":"Harvard Medical School, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corey S.","family":"Cutler","sequence":"additional","affiliation":[{"name":"Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston MA;"},{"name":"Harvard Medical School, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent T.","family":"Ho","sequence":"additional","affiliation":[{"name":"Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston MA;"},{"name":"Harvard Medical School, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph H.","family":"Antin","sequence":"additional","affiliation":[{"name":"Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston MA;"},{"name":"Harvard Medical School, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J.","family":"Soiffer","sequence":"additional","affiliation":[{"name":"Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston MA;"},{"name":"Harvard Medical School, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5526-4669","authenticated-orcid":false,"given":"Jerome","family":"Ritz","sequence":"additional","affiliation":[{"name":"Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston MA;"},{"name":"Harvard Medical School, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2019,4,1]]},"reference":[{"issue":"17","key":"2020021108272901800_B1","doi-asserted-by":"crossref","first-page":"4651","DOI":"10.1182\/blood-2010-11-319509","article-title":"Patient-reported quality of life is associated with severity of chronic graft-versus-host disease as measured by NIH criteria: report on baseline data from the Chronic GVHD Consortium","volume":"117","author":"Pidala","year":"2011","journal-title":"Blood"},{"issue":"1","key":"2020021108272901800_B2","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.pcl.2009.11.003","article-title":"Chronic graft-versus-host disease (GVHD) in children","volume":"57","author":"Baird","year":"2010","journal-title":"Pediatr Clin North Am"},{"issue":"26","key":"2020021108272901800_B3","doi-asserted-by":"crossref","first-page":"2565","DOI":"10.1056\/NEJMra1703472","article-title":"Pathophysiology of chronic graft-versus-host disease and therapeutic targets","volume":"377","author":"Zeiser","year":"2017","journal-title":"N Engl J Med"},{"issue":"3","key":"2020021108272901800_B4","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.4049\/jimmunol.155.3.1151","article-title":"Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases","volume":"155","author":"Sakaguchi","year":"1995","journal-title":"J Immunol"},{"issue":"8","key":"2020021108272901800_B5","doi-asserted-by":"crossref","first-page":"2903","DOI":"10.1182\/blood-2005-03-1257","article-title":"Reduced frequency of FOXP3+ CD4+CD25+ regulatory T cells in patients with chronic graft-versus-host disease","volume":"106","author":"Zorn","year":"2005","journal-title":"Blood"},{"issue":"5","key":"2020021108272901800_B6","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/j.immuni.2009.04.010","article-title":"Mechanisms of foxp3+ T regulatory cell-mediated suppression","volume":"30","author":"Shevach","year":"2009","journal-title":"Immunity"},{"issue":"5","key":"2020021108272901800_B7","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1182\/blood-2015-10-672345","article-title":"Unbalanced recovery of regulatory and effector T cells after allogeneic stem cell transplantation contributes to chronic GVHD","volume":"127","author":"Alho","year":"2016","journal-title":"Blood"},{"issue":"2","key":"2020021108272901800_B8","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.bbmt.2016.09.023","article-title":"The biology of chronic graft-versus-host disease: a task force report from the National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease","volume":"23","author":"Cooke","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"issue":"7","key":"2020021108272901800_B9","doi-asserted-by":"crossref","first-page":"3983","DOI":"10.4049\/jimmunol.172.7.3983","article-title":"IL-2, regulatory T cells, and tolerance","volume":"172","author":"Nelson","year":"2004","journal-title":"J Immunol"},{"issue":"9","key":"2020021108272901800_B10","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1038\/nri1435","article-title":"Tolerance, not immunity, crucially depends on IL-2","volume":"4","author":"Malek","year":"2004","journal-title":"Nat Rev Immunol"},{"issue":"1","key":"2020021108272901800_B11","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1182\/blood-2016-02-702852","article-title":"Efficacy, durability, and response predictors of low-dose interleukin-2 therapy for chronic graft-versus-host disease","volume":"128","author":"Koreth","year":"2016","journal-title":"Blood"},{"issue":"22","key":"2020021108272901800_B12","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1056\/NEJMoa1108188","article-title":"Interleukin-2 and regulatory T cells in graft-versus-host disease","volume":"365","author":"Koreth","year":"2011","journal-title":"N Engl J Med"},{"issue":"4","key":"2020021108272901800_B13","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1182\/blood-2008-02-139154","article-title":"Life after the thymus: CD31+ and CD31- human naive CD4+ T-cell subsets","volume":"113","author":"Kohler","year":"2009","journal-title":"Blood"},{"issue":"11","key":"2020021108272901800_B14","doi-asserted-by":"crossref","first-page":"3270","DOI":"10.1002\/eji.200636976","article-title":"Correlation between recent thymic emigrants and CD31+ (PECAM-1) CD4+ T cells in normal individuals during aging and in lymphopenic children","volume":"37","author":"Junge","year":"2007","journal-title":"Eur J Immunol"},{"issue":"5","key":"2020021108272901800_B15","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1111\/j.1365-2184.1994.tb01421.x","article-title":"The proliferation-associated Ki-67 protein: definition in molecular terms","volume":"27","author":"Duchrow","year":"1994","journal-title":"Cell Prolif"},{"issue":"1","key":"2020021108272901800_B16","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1146\/annurev.immunol.21.120601.141029","article-title":"Control of apoptosis in the immune system: Bcl-2, BH3-only proteins and more","volume":"21","author":"Marsden","year":"2003","journal-title":"Annu Rev Immunol"},{"issue":"19","key":"2020021108272901800_B17","doi-asserted-by":"crossref","first-page":"4099","DOI":"10.1182\/blood-2009-04-217604","article-title":"Comprehensive assessment of T-cell receptor beta-chain diversity in alphabeta T cells","volume":"114","author":"Robins","year":"2009","journal-title":"Blood"},{"issue":"1","key":"2020021108272901800_B18","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s13073-015-0169-8","article-title":"A bioinformatic framework for immune repertoire diversity profiling enables detection of immunological status","volume":"7","author":"Greiff","year":"2015","journal-title":"Genome Med"},{"issue":"2","key":"2020021108272901800_B19","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.immuni.2006.05.016","article-title":"Origin and T cell receptor diversity of Foxp3+CD4+CD25+ T cells","volume":"25","author":"Pacholczyk","year":"2006","journal-title":"Immunity"},{"issue":"4","key":"2020021108272901800_B20","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1182\/blood-2004-11-4557","article-title":"Prospective evaluation of 2 acute graft-versus-host (GVHD) grading systems: a joint Soci\u00e9t\u00e9 Fran\u00e7aise de Greffe de Mo\u00eblle et Th\u00e9rapie Cellulaire (SFGM-TC), Dana Farber Cancer Institute (DFCI), and International Bone Marrow Transplant Registry (IBMTR) prospective study","volume":"106","author":"Cahn","year":"2005","journal-title":"Blood"},{"issue":"4","key":"2020021108272901800_B21","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1038\/nri2061","article-title":"FOXP3 modifies the phenotypic and functional properties of regulatory T cells","volume":"7","author":"Campbell","year":"2007","journal-title":"Nat Rev Immunol"},{"issue":"7129","key":"2020021108272901800_B22","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1038\/nature05479","article-title":"Regulatory T-cell functions are subverted and converted owing to attenuated Foxp3 expression","volume":"445","author":"Wan","year":"2007","journal-title":"Nature"},{"issue":"179","key":"2020021108272901800_B23","doi-asserted-by":"crossref","first-page":"179ra43","DOI":"10.1126\/scitranslmed.3005265","article-title":"Low-dose interleukin-2 therapy restores regulatory T cell homeostasis in patients with chronic graft-versus-host disease","volume":"5","author":"Matsuoka","year":"2013","journal-title":"Sci Transl Med"},{"issue":"3","key":"2020021108272901800_B24","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.bbmt.2012.12.004","article-title":"Fractal organization of the human T cell repertoire in health and after stem cell transplantation","volume":"19","author":"Meier","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"2020021108272901800_B25","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1172\/JCI71691","article-title":"T cell repertoire following autologous stem cell transplantation for multiple sclerosis","volume":"124","author":"Muraro","year":"2014","journal-title":"J Clin Invest"},{"issue":"25","key":"2020021108272901800_B26","doi-asserted-by":"crossref","first-page":"3835","DOI":"10.1182\/blood-2015-03-631853","article-title":"CMV reactivation drives posttransplant T-cell reconstitution and results in defects in the underlying TCR\u03b2 repertoire","volume":"125","author":"Suessmuth","year":"2015","journal-title":"Blood"},{"issue":"24","key":"2020021108272901800_B27","doi-asserted-by":"crossref","first-page":"4955","DOI":"10.1182\/blood-2013-03-489757","article-title":"A distinct evolution of the T-cell repertoire categorizes treatment refractory gastrointestinal acute graft-versus-host disease","volume":"121","author":"Meyer","year":"2013","journal-title":"Blood"},{"issue":"3","key":"2020021108272901800_B28","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1038\/nm.3100","article-title":"Quantitative assessment of T cell repertoire recovery after hematopoietic stem cell transplantation","volume":"19","author":"van Heijst","year":"2013","journal-title":"Nat Med"},{"issue":"5","key":"2020021108272901800_B29","doi-asserted-by":"crossref","first-page":"e86252","DOI":"10.1172\/jci.insight.86252","article-title":"Origin and evolution of the T cell repertoire after posttransplantation cyclophosphamide","volume":"1","author":"Kanakry","year":"2016","journal-title":"JCI Insight"},{"issue":"4","key":"2020021108272901800_B30","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1073\/pnas.0913939107","article-title":"High throughput sequencing reveals a complex pattern of dynamic interrelationships among human T cell subsets","volume":"107","author":"Wang","year":"2010","journal-title":"Proc Natl Acad Sci USA"},{"issue":"1","key":"2020021108272901800_B31","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1111\/imr.12160","article-title":"tTregs, pTregs, and iTregs: similarities and differences","volume":"259","author":"Shevach","year":"2014","journal-title":"Immunol Rev"},{"issue":"7","key":"2020021108272901800_B32","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1038\/mt.2014.50","article-title":"Ultra-low dose interleukin-2 promotes immune-modulating function of regulatory T cells and natural killer cells in healthy volunteers","volume":"22","author":"Ito","year":"2014","journal-title":"Mol Ther"},{"issue":"4","key":"2020021108272901800_B33","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/S2213-8587(13)70113-X","article-title":"Low-dose interleukin 2 in patients with type 1 diabetes: a phase 1\/2 randomised, double-blind, placebo-controlled trial","volume":"1","author":"Hartemann","year":"2013","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"9","key":"2020021108272901800_B34","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1038\/nm.4148","article-title":"Low-dose interleukin-2 treatment selectively modulates CD4(+) T cell subsets in patients with systemic lupus erythematosus","volume":"22","author":"He","year":"2016","journal-title":"Nat Med"},{"issue":"7","key":"2020021108272901800_B35","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1001\/jamadermatol.2014.504","article-title":"Effects of low-dose recombinant interleukin 2 to promote T-regulatory cells in alopecia areata","volume":"150","author":"Castela","year":"2014","journal-title":"JAMA Dermatol"},{"issue":"6","key":"2020021108272901800_B36","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1001\/jamaneurol.2018.0035","article-title":"Association of regulatory t-cell expansion with progression of amyotrophic lateral sclerosis: a study of humans and a transgenic mouse model","volume":"75","author":"Sheean","year":"2018","journal-title":"JAMA Neurol"},{"issue":"22","key":"2020021108272901800_B37","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.1056\/NEJMoa1105143","article-title":"Regulatory T-cell responses to low-dose interleukin-2 in HCV-induced vasculitis","volume":"365","author":"Saadoun","year":"2011","journal-title":"N Engl J Med"},{"issue":"11","key":"2020021108272901800_B38","doi-asserted-by":"crossref","first-page":"6426","DOI":"10.4049\/jimmunol.0903940","article-title":"Cutting edge: mechanisms of IL-2-dependent maintenance of functional regulatory T cells","volume":"185","author":"Barron","year":"2010","journal-title":"J Immunol"},{"issue":"11","key":"2020021108272901800_B39","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1038\/ni.3540","article-title":"An essential role for the IL-2 receptor in Treg cell function","volume":"17","author":"Chinen","year":"2016","journal-title":"Nat Immunol"},{"issue":"12","key":"2020021108272901800_B40","doi-asserted-by":"crossref","first-page":"2707","DOI":"10.1084\/jem.20122759","article-title":"IL-2 coordinates IL-2-producing and regulatory T cell interplay","volume":"210","author":"Amado","year":"2013","journal-title":"J Exp Med"},{"issue":"18","key":"2020021108272901800_B41","doi-asserted-by":"crossref","first-page":"e89278","DOI":"10.1172\/jci.insight.89278","article-title":"Low-dose IL-2 selectively activates subsets of CD4+ Tregs and NK cells","volume":"1","author":"Hirakawa","year":"2016","journal-title":"JCI Insight"},{"issue":"2","key":"2020021108272901800_B42","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1038\/nri1292","article-title":"The many important facets of T-cell repertoire diversity","volume":"4","author":"Nikolich-Zugich","year":"2004","journal-title":"Nat Rev Immunol"},{"issue":"47","key":"2020021108272901800_B43","doi-asserted-by":"crossref","first-page":"47ra64","DOI":"10.1126\/scitranslmed.3001442","article-title":"Overlap and effective size of the human CD8+ T cell receptor repertoire","volume":"2","author":"Robins","year":"2010","journal-title":"Sci Transl Med"},{"issue":"3","key":"2020021108272901800_B44","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1084\/jem.20161318","article-title":"Suppression of lethal autoimmunity by regulatory T cells with a single TCR specificity","volume":"214","author":"Levine","year":"2017","journal-title":"J Exp Med"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/3\/7\/984\/1631539\/advances027474.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/3\/7\/984\/1631539\/advances027474.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,15]],"date-time":"2023-09-15T07:40:25Z","timestamp":1694763625000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/3\/7\/984\/247288\/Functional-analysis-of-clinical-response-to"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,1]]},"references-count":44,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2019,4,9]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2018027474","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,4,1]]}}}